Cargando…
New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53
BACKGROUND: p53 is a transcription factor with tumour suppressor properties, which is able to induce mitochondrial apoptosis independently of its transcriptional activity. We recently synthesised two new compounds (ISA27 and SM13), which block p53-MDM2 interaction and induce apoptosis in p53 wild-ty...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453617/ https://www.ncbi.nlm.nih.gov/pubmed/25422906 http://dx.doi.org/10.1038/bjc.2014.577 |
_version_ | 1782374486296756224 |
---|---|
author | Sorriento, D Del Giudice, C Bertamino, A Ciccarelli, M Gomez-Monterrey, I Campiglia, P Novellino, E Illario, M Trimarco, B De Luca, N Iaccarino, G |
author_facet | Sorriento, D Del Giudice, C Bertamino, A Ciccarelli, M Gomez-Monterrey, I Campiglia, P Novellino, E Illario, M Trimarco, B De Luca, N Iaccarino, G |
author_sort | Sorriento, D |
collection | PubMed |
description | BACKGROUND: p53 is a transcription factor with tumour suppressor properties, which is able to induce mitochondrial apoptosis independently of its transcriptional activity. We recently synthesised two new compounds (ISA27 and SM13), which block p53-MDM2 interaction and induce apoptosis in p53 wild-type (WT) tumour cells. The aim of this study was to verify the effectiveness of these compounds in tumours carrying a mutated form of p53 gene with no transcriptional activity. METHODS: In vitro we evaluated the effectiveness of our compounds in cancer cell lines carrying WT, mutated and null p53 gene. In vivo study was performed in Balb/c nude mice and the mitochondrial-dependent apoptotic signalling was evaluated by western blot. RESULTS: Both ISA27 and SM13 reduced cell proliferation and induced apoptosis in vitro in cells carrying either p53 WT or mutated gene, suggesting that its effect is independent from p53 transcriptional activity. On the contrary, SM13 had no effect in a p53 null cell line. In vivo, ISA27 and SM13 induced cancer cell death in a dose-dependent manner through the activation of the mitochondrial-dependent death signalling in p53-mutated cells. In vivo, SM13 reduced tumour growth. CONCLUSIONS: Our study proposes SM13 as anticancer compound to use for the treatment of p53-dependent tumours, even in the absence of p53 transcriptional activity. |
format | Online Article Text |
id | pubmed-4453617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44536172016-01-06 New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 Sorriento, D Del Giudice, C Bertamino, A Ciccarelli, M Gomez-Monterrey, I Campiglia, P Novellino, E Illario, M Trimarco, B De Luca, N Iaccarino, G Br J Cancer Translational Therapeutics BACKGROUND: p53 is a transcription factor with tumour suppressor properties, which is able to induce mitochondrial apoptosis independently of its transcriptional activity. We recently synthesised two new compounds (ISA27 and SM13), which block p53-MDM2 interaction and induce apoptosis in p53 wild-type (WT) tumour cells. The aim of this study was to verify the effectiveness of these compounds in tumours carrying a mutated form of p53 gene with no transcriptional activity. METHODS: In vitro we evaluated the effectiveness of our compounds in cancer cell lines carrying WT, mutated and null p53 gene. In vivo study was performed in Balb/c nude mice and the mitochondrial-dependent apoptotic signalling was evaluated by western blot. RESULTS: Both ISA27 and SM13 reduced cell proliferation and induced apoptosis in vitro in cells carrying either p53 WT or mutated gene, suggesting that its effect is independent from p53 transcriptional activity. On the contrary, SM13 had no effect in a p53 null cell line. In vivo, ISA27 and SM13 induced cancer cell death in a dose-dependent manner through the activation of the mitochondrial-dependent death signalling in p53-mutated cells. In vivo, SM13 reduced tumour growth. CONCLUSIONS: Our study proposes SM13 as anticancer compound to use for the treatment of p53-dependent tumours, even in the absence of p53 transcriptional activity. Nature Publishing Group 2015-01-06 2014-11-25 /pmc/articles/PMC4453617/ /pubmed/25422906 http://dx.doi.org/10.1038/bjc.2014.577 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Translational Therapeutics Sorriento, D Del Giudice, C Bertamino, A Ciccarelli, M Gomez-Monterrey, I Campiglia, P Novellino, E Illario, M Trimarco, B De Luca, N Iaccarino, G New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 |
title | New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 |
title_full | New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 |
title_fullStr | New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 |
title_full_unstemmed | New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 |
title_short | New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53 |
title_sort | new small molecules, isa27 and sm13, inhibit tumour growth inducing mitochondrial effects of p53 |
topic | Translational Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453617/ https://www.ncbi.nlm.nih.gov/pubmed/25422906 http://dx.doi.org/10.1038/bjc.2014.577 |
work_keys_str_mv | AT sorrientod newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT delgiudicec newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT bertaminoa newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT ciccarellim newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT gomezmonterreyi newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT campigliap newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT novellinoe newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT illariom newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT trimarcob newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT delucan newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 AT iaccarinog newsmallmoleculesisa27andsm13inhibittumourgrowthinducingmitochondrialeffectsofp53 |